NMDAR antagonist for the treatment of pervasive development disorders
A method of treating a pervasive development disorder in a subject includes administering to the subject an amount of an NMDAR antagonist effective to ameliorate biochemical and functional abnormalities in the subject associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein 2 (MeCP2).
1. A method of treating Rett syndrome in a subject in need thereof, the method comprising administering to said subject a sub-anesthetic bolus injection of ketamine at a dosage of 1-20 mg/kg.
2. The method of claim 1 , further comprising administering a TrkB agonist in combination with the NMDAR antagonist.
3. The method of claim 2 , wherein the TrkB agonist N,N′,N″Tris(2-hydroxyethyl)-1,3,5-benzenetricarboxamide or a pharmaceutically effective salt thereof.
4. The method of claim 2 , wherein the NMDAR antagonist ketamine and the TrkB agonist is N,N′,N″Tris(2-hydroxyethyl)-1,3,5-benzenetricarboxamide or a pharmaceutically effective salt thereof.